Trial Information

Phase IIIA Study Comparing the Safety and Effectiveness of MR Guided Focused Ultrasound and External Beam Radiation for Treatment of Metastatic Bone Tumors and Multiple Myeloma

Bone is the third most common organ involved by metastatic disease behind lung and liver
[6]. In breast cancer, bone is the second most common site of metastatic spread, and 90% of
patients dying of breast cancer have bone metastasis. Breast and prostate cancer metastasize
to bone most frequently, which reflects the high incidence of both these tumors, as well as
their prolonged clinical courses. Post-cancer survival has increased with improvement in
early detection and treatments. As a consequence, the number of patients developing
metastatic bone disease during their lifetime has also increased.

Current treatments for patients with bone metastases are primarily palliative and include
localized therapies (radiation and surgery), systemic therapies (chemotherapy, hormonal
therapy, radiopharmaceutical, and bisphosphonates although the primary goal of the use of
these therapies are often to address the disease itself), and analgesics (opioids and
non-steroidal anti-inflammatory drugs). Recently, radiofrequency ablation has been tested as
a treatment option for bone metastases [8]. Currently, an off label use of Cryoablation
techniques are being tested as another alternative for bone Mets palliation. The main goals
of these treatments are improvement of quality of life and functional level. These goals can
be further described:

- Pain relief

- Preservation and restoration of function

- Local tumor control

- Skeletal stabilization

Treatment with external beam radiation therapy (EBRT) is the standard of care for patients
with localized bone pain, and results in the palliation of pain for many of these patients.
Twenty to 30% of patients treated with radiation therapy do not experience pain relief
[9-13]. Re-treatment rates are generally reported in the range of 10-25%. Many patients with
relapsed pain or poor response to initial radiation may be lost to follow up or may not be
referred back to oncologists for consideration of re-radiation. In addition to relapse and
re-treatment, there is an increased risk of pathologic fracture in the peri-radiation
period. The fracture rate reported in radiation studies is generally in the range of 1% to
8%. The hyperemic response weakens the adjacent bone and increases the risk of spontaneous
fracture. Furthermore, patients who have recurrent pain at a site previously irradiated may
not be eligible for further radiation therapy secondary to limitations in normal tissue
tolerance. Hesitation on the part of physicians to use a larger dose may be related to
increased long-term toxicity. Larger radiation dose produces a greater risk of complications
such as fibrosis of normal soft tissue, which can cause a decrement in the quality of life
in cases of life expectancy longer than 6 months. There may also be a greater incidence of
acute side effects of nausea and vomiting if the treatment field includes the stomach. The
percent of patients experiencing vomiting following EBRT ranges from about 5% to 30%.

A palliative treatment for painful bone metastases that is non-invasive, without long-term
toxicity and having minimal complications would be a useful tool for treating physicians and
also a beneficial option for patients suffering from painful bone metastases. Results of
preliminary studies indicate that ExAblate treatment of painful bone metastases may be a
beneficial treatment option [14, 15]. The ExAblate system is a non-invasive thermal ablation
device used in the coagulation of various types of soft tissue. The ExAblate system has the
potential to achieve the first three of the four previously mentioned goals in the treatment
of bone tumors; namely pain relief, preservation and restoration of functional levels and
local tumor control [11].

This study will compare the safety and effectiveness of MR Guided Focused Ultrasound and
External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma.